Alpharma — Thomas Weisel Partners Healthcare Conference 2008
23 slides from Alpharma's conference presentation, Sep 3, 2008
Slide 1: Thomas Weisel Partners Healthcare Conference
(c) King Pharmaceuticals, 2008. No materials contained in this presentation shall be reproduced or redistributed in any form. Thomas Weisel Partners Healthcare Conference September 3, 2008
Slide 2: Forward-looking Statements
Forward-looking Statements This document contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). King Pharmaceuticals, Inc. ("King") disclaims any intent or obligation to update these forward-looking statements, and claims the protection
Slide 3: Who We Are
Who We Are A developer and acquirer of novel branded prescription pharmaceutical products that have significant market potential Focused in three specialty driven markets Neuroscience Hospital Acute Care Medicines A leader and partner of choice in bringing innovative, clinically-differentiated medic
Slide 4: An Integrated Approach to Growth
An Integrated Approach to Growth Specialty Driven Markets Corporate Growth Strategy Organic Growth Maximize current product potential Develop pipeline products Enhance capabilities and maximize efficiency Leverage core capabilities and assets Develop partnerships for promising products and technolog
Slide 5: Proposed Acquisition of Alpharma
Proposed Acquisition of Alpharma
Slide 6: Transaction Rationale: Creates Platform for Long-Term Growth
Transaction Rationale: Creates Platform for Long-Term Growth Creates a leading specialty pharmaceutical company with greater scale and capabilities Expanded portfolio of pain management products - including multiple platform technologies designed to deliver new innovative products Four potential pro
Slide 7: Combined Company Creates A Diversified Pain Portfolio
Combined Company Creates A Diversified Pain Portfolio Combined Skelaxin(r) Avinza(r) Remoxy(r) (NDA Filed) Acurox(tm) (Phase III) Kadian(r) Flector(r) Patch Embeda (NDA Submitted) Ketoprofen Gel (Phase III) T-62 (Phase II) EpiPen(r) Bio-defense products Vanquix (Phase III) King Skelaxin(r) Avinza(r)
Slide 8: Combined R&D Pipeline
Combined R&D Pipeline Product/Platform DESCRIPTION STATUS Remoxy(r) abuse-resistant Long-acting oxycodone capsules NDA Filed/Priority Review Embeda(tm) abuse-deterrent Long-acting morphine tablets NDA Filed/Priority Review Acurox(tm) abuse-deterrent Short-acting oxycodone tablets NDA Submission 4Q/0
Slide 9: Committed to Completing Compelling Transaction
Committed to Completing Compelling Transaction Strong strategic fit Opportunity to increase scale and depth in neuroscience/pain Excellent platform for sustainable, long-term growth We believe proposed combination could receive all necessary regulatory approvals and be completed by the end of 2008
Slide 10: Overview of King's Business
Overview of King’s Business King Pharmaceuticals
Slide 11: Fully-Aligned 690 Person Sales Force
Primary Care Sales Force: 415 Avinza(r) Skelaxin(r) Neuroscience/Pain Specialists Sales Force: 155 Avinza(r) Skelaxin(r) Hospital Specialists Sales Force: 120 Thrombin-JMI(r) Thrombi-Gel(r) Thrombi-Pad(tm) Epistaxis Kit Fully-Aligned 690 Person Sales Force Specialty Markets
Slide 12: Strong Cash Flow
Strong Cash Flow 2005 2006 2007 Projected 2008 Neuroscience 520 466 673 450 (millions)
Slide 13: Hospital Franchise
DEVELOPING CURRENTLY MARKETED Epistaxis Kit CorVue(r) Thrombi-Gel(r) (surgical indication) Thrombi-Paste(tm) Thrombi-Pad(tm) Thrombi-Gel(r) Thrombin-JMI(r) Hospital Franchise Organic Growth
Slide 14: Position King As A Leader In Pain Management
DEVELOPMENT MARKETED Remoxy(r) Acurox(tm) Tablets T-62 Oradur(tm) Platform (PTIE)1 Aversion(r) Technology Platform (Acura)2 Avinza(r) Neuroscience Portfolio Immediate And Extended Release Abuse-deterrent Platforms Position King As A Leader In Pain Management 1 Oradur(tm) is a trademark of Durect Cor
Slide 15: Focus on Pain: Patient Landscape
Focus on Pain: Patient Landscape More than 75 million Americans suffer from pain - more than the number of people with diabetes, heart disease and cancer combined1 An estimated 50 million Americans live with chronic pain, a serious and complex medical condition2 Commonly caused by arthritis, lower b
Slide 16: Issues Facing Pain Treatment
Issues Facing Pain Treatment The undertreatment of pain, paired with abuse of prescription opioids, is a complex health issue facing Americans Pain often remains undertreated because it is difficult to diagnose and manage over a long period of time Effective prescription pain medications are availab
Slide 17: Pain and abuse survey references
1. Substance Abuse and Mental Health Services Administration Office of Applied Studies. Rockville, MD: 2007. Results from the 2006 National Survey on Drug Use and Health: National Findings DHHS Publication No. SMA 07-4293. http://www.oas.samhsa.gov/nsduh/2k6nsduh/2k6Results.pdf. Published September
Slide 18: Remoxy: Extended Release Oxycodone
Remoxy(r): Extended Release Oxycodone King has commercial rights to Pain Therapeutics' Remoxy(r) Remoxy(r) represents a new class of proprietary drugs: extended release opioid analgesics formulated with an extraction resistant technology Technology provides a unique physical barrier Designed to prov
Slide 19: Remoxy: Development Highlights
Remoxy(r): Development Highlights FDA accepted Remoxy NDA for filing and granted priority review PDUFA Date December 10, 2008 Positive Phase III results reported December 2007 The study met the primary endpoint, pain relief vs. placebo (p<0.01), that was prospectively defined by the FDA during the S
Slide 20: Aversion Technology
Aversion(r) Technology Designed to Resist or Deter Methods Used to Abuse Short-Acting Opioids Entered into an exclusive license to develop and commercialize a potentially wide range of opioids utilizing Acura's Aversion(r) Technology platform Recently announced positive Phase III results for ACUROX
Slide 21: Aversion Technology Solution to Common Methods of Abuse
Injection or Oral Consumption Snorting or inhaling Crushed tablets or capsules Swallowing excessive quantities of tablets Nasal Tissue Irritant Discourages nasal abuse Aversion(r) Technology Solution Common Methods of Abuse From extraction of active ingredients from dissolved tablets or capsules Flu
Slide 22: Extended and Immediate Release Opioid Segments
Extended Release Opioid Segment $4 Billion1 19 Million TRx's Current Marketplace OxyContin Duragesic Avinza Kadian MS-Contin Opana ER Immediate Release Opioid Segment $2 Billion1 170 Million TRx's Current Marketplace Vicodin Tylenol w Codeine Percocet Dialaudid Opana IR XRT(tm) compounds Aversion(r)
Slide 23: Positioned for Long-term Growth
Positioned for Long-term Growth Business model leveraging core capabilities and assets in Commercial Operations, R&D and Business Development Focused in specialty driven markets, particularly Neuroscience and Hospital Strong balance sheet and products that generate strong cash flow Disciplined and e
Alpharma — Thomas Weisel Partners Healthcare Conference 2008 on 6ix